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Abstract
 
Osteoclast differentiation factor (ODF, also called RANKL/TRANCE/OPGL) stimulates the
differentiation of osteoclast progenitors of the monocyte/macrophage lineage into osteoclasts
in the presence of macrophage colony-stimulating factor (M-CSF, also called CSF-1). When
mouse bone marrow cells were cultured with M-CSF, M-CSF–dependent bone marrow mac-
rophages (M-BMM
 
f
 
) appeared within 3 d. Tartrate-resistant acid phosphatase–positive osteo-
clasts were also formed when M-BMM
 
f
 
 were further cultured for 3 d with mouse tumor ne-
crosis factor 
 
a
 
 (TNF-
 
a
 
) in the presence of M-CSF. Osteoclast formation induced by TNF-
 
a
 
 was
inhibited by the addition of respective antibodies against TNF receptor 1 (TNFR1) or
TNFR2, but not by osteoclastogenesis inhibitory factor (OCIF, also called OPG, a decoy re-
ceptor of ODF/RANKL), nor the Fab fragment of anti–RANK (ODF/RANKL receptor) anti-
body. Experiments using M-BMM
 
f
 
 prepared from TNFR1- or TNFR2-deficient mice
showed that both TNFR1- and TNFR2-induced signals were important for osteoclast forma-
tion induced by TNF-
 
a
 
. Osteoclasts induced by TNF-
 
a
 
 formed resorption pits on dentine
slices only in the presence of IL-1
 
a
 
. These results demonstrate that TNF-
 
a
 
 stimulates osteo-
clast differentiation in the presence of M-CSF through a mechanism independent of the ODF/
RANKL–RANK system. TNF-
 
a
 
 together with IL-1
 
a
 
 may play an important role in bone re-
sorption of inflammatory bone diseases.
Key words: bone resorption • tumor necrosis factor receptor • nuclear factor-
 
k
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macrophage colony-stimulating factor • interleukin-1
 
Introduction
 
Osteoclasts, the multinucleated giant cells that resorb bone,
develop from hemopoietic cells of the monocyte/macro-
phage lineage (1, 2). Osteoblasts or bone marrow stromal
cells are involved in osteoclastogenesis through a mechanism
involving cell-to-cell contact with osteoclast progenitor
cells. We previously proposed a hypothesis that osteoblasts/
stromal cells express osteoclast differentiation factor (ODF)
 
1
 
in response to several osteotropic factors in supporting os-
teoclast differentiation from their precursors (1, 3, 4). This
working hypothesis was proved by the recent discovery of
a new member of the TNF ligand family, [ODF (5), also
called osteoprotegerin ligand (OPGL) (6)/TNF-related
activation-induced cytokine (TRANCE) (7)/receptor ac-
 
tivator of nuclear factor-
 
k
 
B ligand (RANKL) (8)] as a
 
bone marrow macrophages; M-CSF, macrophage CSF; NF-
 
k
 
B, nuclear
factor 
 
k
 
B; OCIF, osteoclastogenesis inhibitory factor; ODF, osteoclast
differentiation factor; OPGL, osteoprotegerin ligand; RANKL, receptor
activator of NF-
 
k
 
B ligand; RT-PCR, reverse-transcriptase PCR; TRAP,
tartrate-resistant acid phosphatase.
 
Address correspondence to Tatsuo Suda, Department of Biochemistry,
School of Dentistry, Showa University, 1-5-8 Hatanodai, Shinagawa-ku,
Tokyo 142-8555, Japan. Phone: 81-3-3784-8162; Fax: 81-3-3784-5555;
E-mail: suda@showa-u.ac.jp
 
1
 
Abbreviations used in this paper:
 
 1
 
a
 
,25(OH)
 
2
 
D
 
3
 
, 1
 
a
 
,25-dihydroxyvitamin
D
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; JNK, c-Jun NH
 
2
 
-terminal kinase; M-BMM
 
f
 
, M-CSF–dependent 
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membrane-associated factor (3, 4). Osteoclast precursors
that express RANK (9–11), a TNF receptor family mem-
ber, recognize ODF/RANKL through cell-to-cell interac-
tion with osteoblasts/stromal cells, and differentiate into os-
teoclasts in the presence of macrophage CSF (M-CSF, also
called CSF-1) (5, 6). M-CSF has been shown to be an es-
sential factor for osteoclast formation in vivo and in vitro
(12, 13). Osteoclastogenesis inhibitory factor [OCIF, also
called osteoprotegerin (OPG)/TNF receptor-like molecule 1]
is a soluble decoy receptor for ODF/RANKL (14–18).
Nuclear factor 
 
k
 
B (NF-
 
k
 
B) and c-Jun NH
 
2
 
-terminal kinase
(JNK) activated by the RANK-mediated signals in osteoclast
precursors appear to be involved in their differentiation
into osteoclasts (7, 8).
We have also shown that osteoblasts/stromal cells play an
integral role in inducing osteoclast function (19, 20). When
purified osteoclasts formed in cocultures were further cul-
tured on dentine slices, they rapidly underwent apoptosis
and failed to form resorption pits on the slices. Osteoblasts/
stromal cells added to purified osteoclasts greatly stimulated
the survival and resorption activity of osteoclasts through
cell-to-cell contact. Both IL-1
 
a
 
 and soluble ODF/soluble
RANKL (sODF/sRANKL) prolonged the survival of pu-
rified osteoclasts and induced their pit-forming activity (9,
21). OCIF/OPG inhibited both the survival and resorption
activity of osteoclasts supported by not only sODF/sRANKL
(9), but also osteoblasts/stromal cells (4). Fuller et al. (22)
reported that TRANCE (ODF/RANKL) is involved in
osteoclast activation induced by osteoblasts treated with
parathyroid hormone. It was also demonstrated that OPGL
(ODF/RANKL) activated mature osteoclasts in vitro, and
that administration of OPGL induced rapid increases in
blood-ionized calcium levels in mice (23). These results sug-
gest that ODF/RANKL expressed by osteoblasts/stromal cells
is responsible for inducing the differentiation, survival, and
activation of osteoclasts (3, 4). IL-1
 
a
 
 can be substituted for
ODF/RANKL in inducing the survival and activation of
osteoclasts (21).
TNF-
 
a
 
, which is produced by many types of cells, in-
cluding monocytes and macrophages, has been proposed
to be involved in bone resorption, particularly in inflam-
matory bone diseases. Merkel et al. (24) demonstrated that
TNF-
 
a
 
 is involved in orthopedic osteolysis induced by
implant-derived particles. It was also reported that TNF-
 
a
 
and IL-1
 
a
 
 play important roles in bone loss associated with
osteoporosis and periodontitis (25, 26). Lipopolysaccharide-
stimulated osteoclastogenesis has been shown to be medi-
ated by TNF-
 
a
 
 (27). In addition, Pfeilschifter et al. (28) re-
ported that human TNF-
 
a
 
 and IL-1
 
a
 
 stimulated formation
of multinucleated cells with the characteristics of osteoclasts
in human bone marrow cultures. TNF-
 
a
 
 induces a number
of biological responses via two cell-surface receptors termed
TNFR1 and TNFR2 (also called TNFR p55 and TNFR
p75, respectively) (29–31). Both TNFR1 and TNFR2 can
transduce intracellular signals that stimulate the proteolytic
breakdown of I
 
k
 
B, a cytoplasmic inhibitor of NF-
 
k
 
B (32–35).
The activated NF-
 
k
 
B is then translocated into the nucleus,
where it induces the transcription of several TNF-
 
a
 
–respon-
 
sive genes. In addition, the binding of TNF-
 
a
 
 to TNFR1
triggers programmed cell death in many cells. This process
depends on the presence of the “death domain” located in
the cytoplasmic region of TNFR1, which is absent in
TNFR2 (36, 37). It is well established that mouse TNF-
 
a
 
binds to both mouse TNFR1 and TNFR2 with high affin-
ity, while human TNF-
 
a
 
 binds to mouse TNFR1 with
higher affinity than to mouse TNFR2 (29, 30).
In the present study, the role of TNF-
 
a
 
 in osteoclast dif-
ferentiation was studied in detail. Mouse TNF-
 
a
 
 strongly
stimulated the differentiation of M-CSF–dependent mouse
bone marrow macrophages (M-BMM
 
f
 
) into osteoclasts in
the presence of M-CSF. Human TNF-
 
a
 
 induced only a
few osteoclasts in the M-BMM
 
f
 
 cultures. OCIF/OPG did
not inhibit TNF-
 
a
 
–induced osteoclast formation. We report
here that the ODF/RANKL–RANK interaction is not the
sole pathway that leads osteoclast progenitors to differ-
entiation into osteoclasts in vitro; the TNF-
 
a
 
–TNFR1/
TNFR2 interaction can be substituted for the ODF/
RANKL–RANK interaction in inducing osteoclast differen-
tiation under some pathological conditions.
 
Materials and Methods
 
Antibodies and Chemicals.
 
Recombinant mouse sODF/sRANKL
and human OCIF/OPG were prepared as described previously
(5, 16). Recombinant proteins of mouse and human TNF-
 
a
 
, and
human IL-1
 
a
 
 were obtained from R & D Systems, Inc. Human
M-CSF was obtained from Yoshitomi Pharmaceutical Co. Anti–
mouse TNFR1 and TNFR2 antibodies were purchased from
Genzyme Diagnostics. The Fab fragment of anti–RANK poly-
clonal antibody and nonimmunized rabbit immunoglobulin were
prepared using the immunopure Fab preparation kit (Pierce) as
described previously (10). Anti–Mac-1, Moma-2, and F4/80 rat
monoclonal antibodies were obtained from Serotec. (3-[
 
125
 
I]
iodotyrosyl
 
12
 
) Human calcitonin (specific activity, 74 TBqmmol)
was obtained from Amersham International.
 
Mouse M-BMM
 
f
 
 Culture.
 
5–8-wk-old male ddY and C57BL/6J
mice and newborn ddY mice were obtained from Sankyo Labo
Service Co. C57BL/6J mice, in which the TNFR1 or TNFR2
gene had been deleted, were obtained from Jackson Immuno-
Research Laboratories, Inc. Bone marrow cells prepared from the
tibia of ddY mice, TNFR1-deficient mice [TNFR1(
 
2
 
/
 
2
 
)], or
TNFR2-deficient mice [TNFR2(
 
2
 
/
 
2
 
)] were suspended in
 
a
 
MEM containing 10% fetal bovine serum (JRH Biosciences),
and cultured in 48-well plates (1.5 
 
3
 
 10
 
5
 
 cells/0.25 ml per well)
in the presence of M-CSF (100 ng/ml). After culturing for 3 d,
nonadherent cells were completely removed from the culture by
pipetting. Characteristics of adherent cells were examined by
staining with antibodies against Mac-1, Moma-2, and F4/80 anti-
gens using a Vectastain ABC AP kit and Vector Red (Vector
Laboratories, Inc.). Positive cells were stained red (see Fig. 1). As
almost all of the adherent cells were positive for these antibodies,
we called the adherent cells M-BMM
 
f
 
. M-BMM
 
f
 
 were further
cultured for 3 d with either cytokine of sODF/sRANKL, mouse
TNF-
 
a
 
, human TNF-
 
a
 
, or IL-1
 
a
 
 in the presence or absence of
OCIF/OPG and/or M-CSF. Some cultures were also treated
with anti–mouse TNFR1 or TNFR2 antibody, or the Fab frag-
ment of anti–RANK antibody. Cells were then fixed and stained
for tartrate-resistant acid phosphatase (TRAP) as described previ-
ously (38). Cells were also stained for alkaline phosphatase (a 
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marker enzyme of osteoblasts) as described previously (38). Posi-
tive cells appeared as blue cells. The number of TRAP-positive
cells, including mononuclear and multinucleated cells, was scored
under microscopic examination. In some experiments, TRAP-
positive cells containing more than three nuclei were also
counted as TRAP-positive multinucleated cells.
 
Autoradiography for Calcitonin Binding.
 
Bone marrow cells of ddY
mice (2 
 
3
 
 10
 
5
 
 cells/chamber) were plated on Lab-Tek 8-cham-
ber slides (Nalge Nunc International). Cells were first cultured
with M-CSF (100 ng/ml) for 3 d, and further cultured with or
without cytokines for 3 d. Cultures were then treated with 0.2
nM [
 
125
 
I]-human calcitonin for 1 h at room temperature. After
washing twice with PBS, cells were fixed with 0.1 M cacodylate
buffer, pH 7.4, containing 1% formaldehyde and 1% glutaralde-
hyde, stained for TRAP, and processed for autoradiography as
described previously (38). Nonspecific binding of [
 
125
 
I]-labeled
calcitonin was assessed in the presence of an excess amount (200
nM) of unlabeled eel calcitonin (Asahi Chemical Industry).
 
Pit Formation Assay.
 
To determine resorption activity of TRAP-
positive cells, bone marrow cells of ddY mice (2 
 
3
 
 10
 
5
 
 cells/well)
were plated on dentine slices (4 mm in diameter) that had been
placed in 48-well culture plates. Bone marrow cells were first
cultured with M-CSF (100 ng/ml) for 3 d. The slices, on which
M-BMM
 
f
 
 were formed, were then well washed with 
 
a
 
MEM to
remove nonadherent cells, and further cultured with or without
cytokines for an additional 3 d. Some dentine slices were sub-
jected to TRAP staining. The remaining slices were cleaned by
ultrasonication in 1 M NH
 
4
 
OH to remove adherent cells and
stained with Mayer’s hematoxylin to visualize resorption pits as
described (38). The number of TRAP-positive cells on the slices
and that of resorption pits were counted under microscopic ex-
amination.
 
Survival Assay of Osteoclasts.
 
Osteoblasts obtained from the cal-
varia of newborn ddY mice and bone marrow cells from ddY
mice were cocultured in 
 
a
 
MEM containing 10% fetal bovine se-
rum, 1
 
a
 
,25-dihydroxyvitamin D
 
3
 
 [1
 
a
 
,25(OH)
 
2
 
D
 
3
 
] (1028 M) (Wako
Pure Chemical Co.), and prostaglandin E2 (1026 M) (Sigma
Chemical Co.) in 100-mm–diameter dishes coated with Type I
collagen gels (Nitta Gelatin Co.) as described previously (38). Os-
teoclasts formed within 6 d were recovered from the dishes by
treating with 0.2% collagenase (crude osteoclasts). To purify os-
teoclasts, the crude osteoclast preparation was replated and cul-
tured for 8 h. Osteoblasts were then removed by treating with
PBS containing 0.001% pronase E and 0.02% EDTA (38). Some
of the cultures were then stained for TRAP. The other cultures
were further incubated for 36 h in the presence or absence of
mouse TNF-a (20 ng/ml), human TNF-a (20 ng/ml), IL-1a
(10 ng/ml), or sODF/sRANKL (100 ng/ml), and stained for
TRAP. TRAP-positive multinucleated cells containing more
than three nuclei were counted as living osteoclasts.
Polymerase Chain Reaction Amplification of Reverse-transcribed mRNA.
For semiquantitative reverse-transcriptase PCR (RT-PCR) anal-
ysis, total RNA was extracted using Trizol solution (GIBCO
BRL) from freshly isolated bone marrow cells, M-BMMf, and
purified osteoclasts. Purified osteoclasts were obtained from co-
cultures of mouse bone marrow cells and calvarial osteoblasts as
described previously (21). First strand cDNA was synthesized
from total RNA with random primers and was subjected to PCR
amplification with EX Taq polymerase (Takara Shuzo) using spe-
cific PCR primers: mouse TNFR1, 59-GAGTGCTGACCTA-
TAACACATTCCT-39 (forward, nucleotides 3152–3176) and
59-CATCTTGCCAGTTCAAAACTAACTT-39 (reverse, nucleo-
tides 3553–3577); mouse TNFR2, 59-CATTCTAAGAACAATT-
CCATCTGCT-39 (forward, nucleotides 246–270) and 59-GGG-
TACTGGAGACAGGAGAACTAA-39 (reverse, nucleotides 961–
984); mouse RANK, 59-ACACCTGGAATGAAGAAGATAA-
ATG-39 (forward, nucleotides 260–284) and 59-AGCCACTAC-
TACCACAGAGATGAAG-39 (reverse, nucleotides 684–708);
mouse c-Fms, 59-AACAAGTTCTACAAACTGGTGAAGG-39
(forward, nucleotides 2653–2677) and 59-GAAGCCTGTAGTCT-
AAGCATCTGTC-39 (reverse, nucleotides 3381–3405); mouse
glyceraldehyde-3-phosphate dehydrogenase, 59-ACCACAGTCC-
ATGCCATCAC-39 (forward, nucleotides 566–585) and 59-TCC-
ACCACCCTGTTGCTGTA-39 (reverse, nucleotides 998–1017).
The PCR products were separated by electrophoresis on a 2%
agarose gel.
Electrophoretic Mobility Shift Assay. Mouse M-BMMf were treated
with sODF/sRANKL (100 ng/ml), mouse TNF-a (20 ng/ml),
or human TNF-a (20 ng/ml) for 1 h. Nuclear extracts were then
prepared from M-BMMf as described previously (39). An NF-
kB–binding oligonucleotide sequence 59-AGCTTGGGGACTT-
TCCGAG-39 was used as a radioactive DNA probe. DNA bind-
ing reaction was performed at room temperature in a volume of
30 ml, which contained the binding buffer (10 mM Tris/HCl,
pH 7.5, 1 mM EDTA, 4% glycerol, 100 mM NaCl, 5 mM
DTT, 100 mg/ml of BSA), 3 mg of poly(dI-dC), 105 cpm of a
32P-labeled probe, and 8 mg of nuclear proteins. After incubation
for 15 min, the samples were electrophoresed on native 5% acryl-
amide/0.25 3 Tris-borate-EDTA gels. The gels were dried and
exposed to x-ray film.
Statistical Analysis.  Significance of differences was determined
using Student’s t test.
Results
When mouse bone marrow cells were cultured with
M-CSF for 3 d, adherent cells of uniform size and shape ap-
peared on the culture plate. Almost all of the adherent cells
strongly expressed antigens such as Mac-1, Moma-2, and
Figure 1. Expression of macrophage-
associated antigens by M-BMMf.
Mouse bone marrow cells of ddY
mice were cultured with M-CSF
(100 ng/ml). After culturing for 3 d,
nonadherent cells were completely
removed, and remaining adherent
cells were fixed and stained with an-
tibodies against Mac-1, Moma-2,
and F4/80 antigens. Cells express-
ing each antigen were stained red.
Note that almost all of the adherent
cells are positive for Mac-1, Moma-2,
and F4/80. Bar, 100 mm.278 TNF-a Induces Osteoclast Differentiation
F4/80, which are specific for macrophages (Fig. 1). In this
study, these adherent cells were called M-BMMf. Typically,
104 M-BMMf were obtained when 105 bone marrow cells
were cultured for 3 d in the presence of M-CSF. There were
very few alkaline phosphatase–positive stromal cells detect-
able in the M-BMMf preparation (data not shown).
When M-BMMf were further cultured with sODF/
sRANKL and M-CSF, TRAP-positive mononuclear and
multinucleated cells were formed within 3 d (Fig. 2, A and
B). In the absence of M-CSF, most of the M-BMMf died
within 3 d. No TRAP-positive cells were formed when
M-CSF was not added, even in the presence of sODF/
sRANKL. Although varied in each experiment, 40–80% of
the M-BMMf usually differentiated into TRAP-positive
cells in response to sODF/sRANKL and M-CSF. When
nonadherent cells, which were recovered from bone mar-
row cultures treated for 3 d with M-CSF, were further cul-
tured for 3 d with ODF/RANKL and M-CSF, only a few
TRAP-positive cells were formed (data not shown). This
suggests that osteoclast progenitors are present preferen-
Figure 2. Effects of sODF/
sRANKL, and mouse and human
TNF-a on TRAP-positive cell for-
mation in M-BMMf cultures. Bone
marrow cells of ddY mice were cul-
tured with M-CSF for 3 d to prepare
M-BMMf. (A) M-BMMf were
further cultured for 3 d with either
sODF/sRANKL (100 ng/ml), mouse
TNF-a (20 ng/ml), human TNF-a
(20 ng/ml), IL-1a (10 ng/ml), or
1a,25(OH)2D3 (1028 M) in the pres-
ence and absence of M-CSF (100 ng/
ml). Cells were then fixed and stained
for TRAP and the number of TRAP-
positive cells were scored. (B) TRAP
staining of M-BMMf cultures
treated with vehicle (control), sODF/
sRANKL (100 ng/ml), mouse TNF-a
(20 ng/ml), human TNF-a (20 ng/
ml), or IL-1a (10 ng/ml) in the pres-
ence of M-CSF (100 ng/ml) for 3 d.
Arrows in the culture treated with
human TNF-a indicate TRAP-posi-
tive mononuclear cells. M-BMMf
cultures treated with 1a,25(OH)2D3,
(1028 M) in the presence of M-CSF
(100 ng/ml) for 3 d were double
stained for TRAP and alkaline phos-
phatase. The inset shows alkaline
phosphatase staining of primary osteo-
blasts cultured for 3 d in the presence
of 1a,25(OH)2D3 (1028 M) as the
control. Bar, 100 mm. (C) M-BMMf
were further cultured for 3 d with
increasing concentrations of mouse
TNF-a in the presence of M-CSF
(100 ng/ml). Cells were then fixed
and stained for TRAP, and the num-
ber of TRAP-positive cells was scored.
Results were expressed as the means 6
SEM of three to four cultures. Similar
results were obtained in three inde-
pendent experiments.279 Kobayashi et al.
tially as adherent cells in M-CSF–treated bone marrow
cells. Surprisingly, mouse TNF-a stimulated TRAP-posi-
tive cell formation from M-BMMf in the presence of
M-CSF in a dose-dependent manner (Fig. 2, A and C).
Morphology of TRAP-positive cells induced by mouse
TNF-a was quite similar to that induced by sODF/sRANKL
(Fig. 2 B). Repeated experiments showed that 3–5% of the
TRAP-positive cells induced by either mouse TNF-a or
ODF/RANKL were multinucleated cells, which contained
more than three nuclei. In contrast, human TNF-a at 20
ng/ml induced a few TRAP-positive mononuclear cells in
M-BMMf cultures (Fig. 2 B). Neither human nor mouse
TNF-a induced apoptosis of M-BMMf in the presence or
absence of M-CSF. No TRAP-positive cells were formed
in M-BMMf cultures treated with IL-1a at 10 ng/ml even
in the presence of M-CSF (Fig. 2, A and B). Addition of
1a,25(OH)2D3 at 1028 M to the M-BMMf cultures also
failed to induce TRAP-positive cells, irrespective of the pres-
ence or absence of M-CSF (Fig. 2, A and B). Alkaline phos-
phatase–positive cells were not detected in the M-BMMf
preparation after culture for 3 d with 1a,25(OH)2D3 and
M-CSF (Fig. 2 B). Mouse TNF-a (20 ng/ml) stimulated
TRAP-positive cell formation in cultures of mouse spleen
cells or whole bone marrow cells in the presence of M-CSF
(100 ng/ml) (data not shown). We used M-BMMf instead
of whole bone marrow cells in this experiment to avoid con-
tamination of cells other than osteoclast progenitors.
We previously reported that osteoclasts formed in the cocul-
tures expressed mRNAs of TNFR1, TNFR2, and RANK
(9). Using a semiquantitative RT-PCR, it was shown that not
only purified osteoclasts but also M-BMMf expressed these
mRNAs (Fig. 3 A). Both M-BMMf and osteoclasts ex-
pressed c-Fms mRNA as well. Freshly isolated bone marrow
cells expressed mRNAs of TNFR1, TNFR2, RANK, and
c-Fms only weakly, when compared with M-BMMf and
osteoclasts (Fig. 3 A). An electrophoretic mobility shift assay
revealed that mouse TNF-a, human TNF-a, and sODF/
sRANKL all activated NF-kB in M-BMMf (Fig. 3 B).
TRAP-positive cell formation induced by sODF/sRANKL
was inhibited completely by simultaneously adding OCIF/
OPG (Fig. 4 A, top). In contrast, TRAP-positive cell for-
mation was similarly induced by mouse TNF-a irrespec-
tive of the presence or absence of OCIF/OPG (Fig. 4 A,
bottom). Although these results suggest that TNF-a in-
duces osteoclast differentiation through TNFR1/TNFR2,
there were still two possibilities that TNF-a directly binds to
RANK or TNF-a increases endogenous production of some
factor(s) that can interact with RANK. To exclude these
possibilities, the Fab fragment of polyclonal antibodies
against the extracellular domain of RANK was used in the
Figure 3. Expression of mRNAs of TNFR1, TNFR2, RANK, and
c-Fms by M-BMMf (A) and the effects of mouse and human TNF-a on
the activation of NF-kB in M-BMMf (B). (A) Total RNA was extracted
from bone marrow cells, M-BMMf, and purified osteoclasts of ddY
mouse origin, and subjected to semiquantitative PCR analysis for
TNFR1, TNFR2, RANK, c-Fms, and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) using the specific primer pairs described in Materials
and Methods. PCR was performed under conditions determined to be in
the linear range of product formation. (B) M-BMMf were treated with
sODF/sRANKL (100 ng/ml), mouse TNF-a (20 ng/ml), or human
TNF-a (20 ng/ml) for 1 h. Nuclear extracts were prepared and analyzed
by an electrophoretic mobility shift assay with an NF-kB–binding oligo-
nucleotide probe as described in Materials and Methods. Similar results
were obtained in two independent experiments.
Figure 4. TRAP-positive cell formation induced by mouse TNF-a in
M-BMMf cultures caused by a mechanism independent of ODF/
RANKL–RANK interaction. M-BMMf prepared from ddY mice were
further cultured for 3 d with sODF/sRANKL (100 ng/ml) (top) or
mouse TNF-a (20 ng/ml) (bottom) in the presence of M-CSF (100 ng/
ml). M-BMMf were simultaneously treated with or without OCIF/
OPG (100 ng) (A), or treated with the Fab fragment of anti–RANK anti-
body (10 mg/ml) or the Fab fragment of control IgG (10 mg/ml) (B). Af-
ter culturing for an additional 3 d, cells were fixed and stained for TRAP.
Results were expressed as the means 6 SEM of three cultures. Similar re-
sults were obtained in three independent experiments. *Significantly dif-
ferent from the control culture; P , 0.01.280 TNF-a Induces Osteoclast Differentiation
next experiment. We previously reported that the anti–
RANK antibody induced osteoclastogenesis in the pres-
ence of M-CSF, probably through clustering of RANK
(10). In contrast, the Fab fragment of the antibody blocked
the binding of ODF/RANKL to RANK, causing the inhibi-
tion of the sODF/sRANK-mediated osteoclastogenesis (10).
The Fab fragment of the anti–RANK antibody inhibited
TRAP-positive cell formation induced by sODF/sRANK
(Fig. 4 B). In contrast, the Fab fragment of the anti–RANK
antibody showed no inhibitory effect on mouse TNF-a–
induced TRAP-positive cell formation in M-BMMf cul-
tures. These results indicate that TNF-a stimulates TRAP-
positive cell formation by a mechanism independent of the
ODF/RANKL–RANK interaction.
We next examined effects of blocking antibodies against
TNFR1 or TNFR2 on TRAP-positive cell formation in
M-BMMf cultures treated with mouse TNF-a or sODF/
sRANKL in the presence of M-CSF (Fig. 5 A). Both anti-
bodies showed no inhibitory effect on the sODF/sRANKL-
induced TRAP-positive cell formation, but each of the
two antibodies strongly inhibited TRAP-positive cell for-
mation induced by mouse TNF-a (Fig. 5 A). To further
confirm the possibility that both TNFR1 and TNFR2 play
important roles in TNF-a–induced TRAP-positive cell
formation, M-BMMf were prepared from TNFR1(2/2),
TNFR2(2/2), and the control C57BL/6J (wild type) mice,
and compared their capacity to differentiate into TRAP-
positive cells in the presence of mouse TNF-a plus M-CSF
or sODF/sRANKL plus M-CSF (Fig. 5 B). In the presence
of sODF/sRANKL, the number of TRAP-positive cells
formed from TNFR1(2/2) and TNFR2(2/2) M-BMMf
culture was similar to that from the control (wild type)
M-BMMf (Fig. 5 B). In contrast, no TRAP-positive cells
were observed in TNFR1(2/2) M-BMMf cultures treated
with mouse TNF-a (Fig. 5 B). TRAP-positive cell forma-
tion induced by mouse TNF-a was markedly reduced in
TNFR2(2/2) M-BMMf cultures in comparison with that
in the control (wild type) cultures. These results confirmed
that both TNFR1- and TNFR2-mediated signals were im-
portant for TNF-a–induced osteoclast differentiation.
Autoradiography using [125I]-labeled calcitonin showed
that numerous grains, as a result of the binding of labeled
calcitonin, accumulated on TRAP-positive cells induced
by mouse TNF-a together with M-CSF even in the pres-
ence of OCIF/OPG (Fig. 6 A). In agreement with previ-
ous findings (5), numerous grains of the binding of labeled
calcitonin were observed on TRAP-positive cells induced
by sODF/sRANKL in the presence of M-CSF (Fig. 6 B).
However, no calcitonin receptor-positive cells appeared in
M-BMMf cultures treated with sODF/sRANKL plus
M-CSF in the presence of OCIF/OPG (Fig. 6 C). The
binding of [125I]-labeled calcitonin to TRAP-positive cells
was inhibited by an excess amount of unlabeled calcitonin
simultaneously added (data not shown), suggesting that
TRAP-positive cells induced by mouse TNF-a as well as
sODF/RANKL expressed calcitonin receptors.
Figure 5. TRAP-positive cell formation induced by mouse TNF-a in
M-BMMf requires both TNFR1- and TNFR2-mediated signals. (A)
M-BMMf prepared from ddY mice were further cultured for 3 d with
sODF/sRANKL (100 ng/ml) (top) or mouse TNF-a (20 ng/ml) (bot-
tom) in the presence of M-CSF (100 ng/ml). M-BMMf were simulta-
neously treated with or without control IgG (30 mg/ml), anti–TNFR1
antibody (10 mg/ml), or anti–TNFR2 antibody (30 mg/ml). After cul-
turing for an additional 3 d, cells were fixed and stained for TRAP.
The number of TRAP-positive cells was scored. Results were expressed
as the means 6 SEM of three cultures. Similar results were obtained in
three independent experiments. (B) M-BMMf were prepared from nor-
mal C57BL/6J mice (wild type), TNFR1-deficient C57BL/6J mice
[TNFR1(2/2)] or TNFR2-deficient C57BL/6J mice [TNFR2(2/2)].
M-BMMf were further cultured with sODF/sRANKL (100 ng/ml)
(top) or mouse TNF-a (20 ng/ml) in the presence of M-CSF (100 ng/
ml) (bottom). After culturing for an additional 3 d, cells were fixed and
stained for TRAP. The number of TRAP-positive cells was scored. Re-
sults were expressed as the means 6 SEM of four mice in each group.
*Significantly different from the control (A) or wild type (B); P , 0.01.
Figure 6. Autoradiography for [125I]-calcitonin binding in M-BMMf
cultures. Bone marrow cells of ddY mice were first cultured for 3 d on
LAB-Tek chamber slides in the presence of M-CSF (100 ng/ml). (A)
M-BMMf formed on the chamber slides were further cultured for 3 d
with mouse TNF-a (20 ng/ml) plus M-CSF (100 ng/ml) in the presence
of OCIF/OPG (100 ng/ml). (B and C) M-BMMf were further cultured
for 3 d with sODF/sRANKL (100 ng/ml) plus M-CSF (100 ng/ml) in
the absence (B) and presence (C) of OCIF/OPG (100 ng/ml). Cells were
then treated with 0.2 nM [125I]-human calcitonin, stained for TRAP, and
processed for autoradiography. Similar results were obtained in two inde-
pendent experiments. Bar, 100 mm.281 Kobayashi et al.
We previously reported that IL-1a, M-CSF, and sODF/
sRANKL similarly stimulated the survival of purified os-
teoclasts via the respective receptors (9, 21). Using purified
osteoclasts, we next examined whether TNF-a supports
the survival of osteoclasts (Fig. 7). Most of the osteoclasts
died within 36 h after removal of osteoblasts in the pres-
ence and absence of OCIF/OPG. Treatment of purified
osteoclast preparations with mouse TNF-a stimulated the
survival of osteoclasts. OCIF/OPG showed no inhibitory
effects on the survival of osteoclasts supported by mouse
TNF-a (Fig. 7). In agreement with previous finding (9),
sODF/sRANKL and IL-1a stimulated the survival of pu-
rified osteoclasts. OCIF/ OPG strongly inhibited the sur-
vival of osteoclasts supported by sODF/sRANKL but not
by IL-1a (Fig. 7).
We previously reported that purified osteoclasts rapidly
died and did not form resorption pits on dentine slices (19,
20). The pit-forming activity of purified osteoclasts was
greatly recovered by adding either osteoblasts/stromal cells,
IL-1a, or sODF/sRANKL (9, 19, 21). When M-BMMf
were prepared on dentine slices, and cultured with mouse
TNF-a, IL-1a, or mouse TNF-a plus IL-1a in the pres-
ence of M-CSF and OCIF/OPG, a similar number of
TRAP-positive cells appeared on dentine slices in response
to mouse TNF-a irrespective of the presence and absence of
IL-1a (Fig. 8, A and B). However, resorption pits on the
slices were detected only in the presence of both mouse
TNF-a and IL-1a (Fig. 8, A and B). These results suggest
that TNF-a stimulates the differentiation and survival of
osteoclasts, but not the function of osteoclasts.
Figure 7. Effects of mouse TNF-a on the survival of purified osteoclasts.
Purified osteoclasts of ddY mouse origin were prepared as described in Ma-
terials and Methods. Purified osteoclasts were incubated with mouse TNF-a
(20 ng/ml), sODF/sRANKL (100 ng/ml), IL-1a (10 ng/ml), or vehicle
(control) in the presence or absence of OCIF/OPG (100 ng/ml). Before
(A) and after (B) incubation of purified osteoclasts for 36 h, TRAP-positive
osteoclasts containing more than three nuclei were counted. Results were
expressed as the means 6 SEM of three cultures. Similar results were ob-
tained from three independent experiments. *Significantly different from
the culture treated without OCIF/OPG; P , 0.01.
Figure 8. Pit-forming activity of TRAP-positive cells formed in
M-BMMf cultures. (A) Mouse bone marrow cells were cultured on den-
tine slices for 3 d in the presence of M-CSF (100 ng/ml). M-BMMf
formed on the slices were further cultured with mouse TNF-a (20 ng/ml),
IL-1a (10 ng/ml), or mouse TNF-a (20 ng/ml) plus IL-1a (10 ng/ml) in
the presence of M-CSF (100 ng/ml) and OCIF/OPG (200 ng/ml). After
culturing for an additional 3 d, some dentine slices were stained for TRAP.
The remaining dentine slices were cleaned by ultrasonication to remove ad-
herent cells, and stained with Mayer’s hematoxylin to visualize resorption
pits. The number of TRAP-positive cells and that of resorption pits on
dentine slices were counted. Results were expressed as the means 6 SEM
of three cultures. (B) TRAP staining (top) and resorption pits (bottom) on
dentine slices obtained from cultures treated with mouse TNF-a (left) and
from cultures treated with mouse TNF-a plus IL-1a (right). Similar results
were obtained in three sets of independent experiments. Bar, 100 mm.282 TNF-a Induces Osteoclast Differentiation
Discussion
Since the discovery of the ODF/RANKL–RANK signal
transduction, it has been believed that ODF/RANKL is
the sole factor responsible for inducing osteoclast differenti-
ation. This notion was supported by the finding that the
targeted disruption of the gene encoding OPGL (ODF/
RANKL) in mice developed severe osteopetrosis with
complete absence of TRAP-positive cells in bone tissues
(40). However, the present study clearly shows that TNF-a
together with M-CSF induces TRAP-positive cell forma-
tion in M-BMMf cultures without any help of osteoblasts/
stromal cells. Alkaline phosphatase–positive cells were sel-
dom detected in the M-BMMf preparation even after cul-
ture for an additional 3 d. No TRAP-positive cells were
formed in the cultures of the M-BMMf preparation treated
with 1a,25(OH)2D3 in the presence or absence of M-CSF.
A recent study on vitamin D receptor knockout mice proved
that the target cells of 1a,25(OH)2D3 in inducing osteoclast
formation are osteoblasts/stromal cells, but not osteoclast
progenitors (41). These results suggest that even if a small
number of stromal cells were present in the M-BMMf
preparation, they could not support osteoclast formation.
Like authentic osteoclasts, TRAP-positive cells formed
in response to TNF-a and M-CSF expressed calcitonin re-
ceptors. TNF-a–induced TRAP-positive cells formed re-
sorption pits only in the presence of IL-1a. This property
of TRAP-positive cells induced by TNF-a is recognized in
ODF/RANKL-induced osteoclasts as well (19, 21). M-CSF
was essentially required for osteoclast formation induced by
TNF-a as in sODF/sRANKL-induced osteoclast forma-
tion. These results indicate that TNF-a–induced TRAP-pos-
itive cells in M-BMMf cultures satisfy major criteria for os-
teoclasts. OCIF/OPG and the Fab fragment of anti–RANK
antibody did not inhibit the TNF-a–induced TRAP-positive
and calcitonin receptor-positive osteoclast formation. Us-
ing RT-PCR, we found that M-BMMf expressed ODF/
RANKL mRNA, but its level was very low and was not up-
regulated by adding mouse TNF-a (data not shown). These
results further confirm that ODF/RANKL is not involved in
the TNF-a–induced osteoclast formation in M-BMMf cul-
tures. In our preliminary experiments, human TNF-a stimu-
lated the formation of TRAP- and vitronectin receptor
(23C6)–positive osteoclast-like cells in cultures of human pe-
ripheral blood mononuclear cells even in the presence of
OCIF/OPG (data not shown). These results suggest that the
ODF/RANKL–RANK signaling system is not the sole path-
way for inducing osteoclast differentiation in vitro (Fig. 9).
M-BMMf expressed both TNFR1 and TNFR2. Acti-
vation of NF-kB in M-BMMf was induced not only by
mouse TNF-a, but also human TNF-a. However, the po-
tency of human TNF-a to induce TRAP-positive osteo-
clast formation in M-BMMf cultures was much weaker
than that of mouse TNF-a. Anti–TNFR1 antibody com-
pletely inhibited osteoclast formation induced by mouse
TNF-a, but not osteoclast formation by sODF/sRANKL.
M-BMMf prepared from TNFR1(2/2) mice did not dif-
ferentiate  into TRAP-positive cells in response to mouse
TNF-a. These results suggest that TNFR1-mediated sig-
nals are essential for TRAP-positive cell formation induced
by TNF-a. Furthermore, addition of anti–TNFR2 antibody
to M-BMMf cultures significantly inhibited TRAP-posi-
tive osteoclast formation induced by mouse TNF-a. In ad-
dition, TRAP-positive osteoclast formation induced by
mouse TNF-a was markedly reduced in TNFR2(2/2)
M-BMMf cultures. These results suggest that TNFR2-
mediated signals play important roles in osteoclast differen-
tiation. Collectively, both signals mediated by TNFR1 and
TNFR2 appear to be required for inducing osteoclast for-
mation at the level similar to ODF/RANKL-induced os-
teoclast formation (Fig. 9). Using the anti–TNFR1 and
–TNFR2 antibody, it was clearly shown that only TNFR1-
mediated signals led to the endotoxin-induced shock and
protective response against Listeria monocytogenes infection,
and both TNFR1- and TNFR2-mediated signals were re-
quired for the development of TNF-a–induced skin necro-
sis in mice (42). Abu-Amer et al. (27) reported that osteo-
clastogenesis induced by lipopolysaccharides is mediated by
TNF-a via TNFR1. They also showed that human as well as
mouse TNF-a stimulated the expression of c-Src, a marker
protein of osteoclasts, in mouse bone marrow macrophages
(27). These findings support the conclusion that TNFR1-
mediated signals are essential for osteoclast differentiation.
We previously reported that purified osteoclasts rapidly
underwent apoptosis and did not form resorption pits on den-
tine slices (19). IL-1a as well as sODF/sRANKL induced
Figure 9. Schematic representation of ligand-receptor systems in osteo-
clast differentiation and function regulated by TNF-a, ODF/RANKL, and
IL-1a. TNF-a and ODF/RANKL independently stimulate osteoclast
differentiation. Osteoclast differentiation induced by TNF-a occurs via
TNFR1 and TNFR2 expressed by osteoclast precursors. ODF/RANKL
induces osteoclast differentiation through RANK-mediated signals. M-CSF
is a common factor required for both TNF-a– and ODF/RANKL-
induced osteoclast differentiation. Activation of osteoclasts is induced by
ODF/RANKL and IL-1a through RANK and type 1 IL-1 receptor, re-
spectively. Common signaling cascades such as NF-kB and JNK activa-
tion may be involved in the differentiation and activation of osteoclasts
induced by TNF-a, ODF/RANKL, and IL-1a.283 Kobayashi et al.
the survival and pit-forming activity of purified osteoclasts
(9, 21). The present study showed that the survival of puri-
fied osteoclasts was stimulated by human as well as mouse
TNF-a. However, resorption pits were not formed on den-
tine slices in M-BMMf cultures treated with mouse TNF-a
and M-CSF. Resorption pits were observed on dentine
slices in the M-BMMf culture further treated with IL-1a.
These results suggest that TNF-a is capable of stimulating
the differentiation and survival of osteoclasts, but not the pit-
forming activity of osteoclasts. On the other hand, ODF/
RANKL supports all the processes of differentiation, survival,
and activation of osteoclasts (Fig. 9).
Determination of signals involved in osteoclast differen-
tiation is an important issue in the research on osteoclast bi-
ology. At present, two signals, NF-kB and JNK, have been
proposed to be involved in osteoclast differentiation. Hsu
et al. (11) reported that ODF/RANKL stimulated JNK ac-
tivity of murine myeloid RAW-264.7 cells and induced
differentiation of these cells into osteoclasts. Activation of
NF-kB in RAW-264.7 cells was not induced by ODF/
RANKL. This indicates that the signals mediated by JNK
rather than NF-kB are important for ODF/RANKL-induced
osteoclast differentiation in RAW-264.7 cells. In our ex-
periments, IL-1 activated NF-kB in M-BMMf (data not
shown), but failed to induce osteoclast differentiation in
M-BMMf cultures. These results suggest that some other
signals than NF-kB may play an important role in osteo-
clast differentiation. RAW-264.7 cells differentiated into
TRAP-positive cells in response to mouse TNF-a as well
as ODF/RANKL (data not shown). Possible involvement
of JNK and NF-kB in osteoclastogenesis is currently under
investigation in our laboratories.
Mounting evidence has demonstrated that TNF receptor
family members interact with TNF receptor–associated fac-
tors (TRAFs) to modulate JNK and NF-kB activity as well
as apoptosis in the target cells (43, 44). TRAF2 has been
shown to be an adaptor protein for TNFR1- and TNFR2-
mediated signals in the target cells (43, 44). Recent studies
have demonstrated that the cytoplasmic tail of RANK in-
teracts with TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6
(45–48). Recently, it was reported that TRAF6 knockout
mice developed severe osteopetrosis (49, 50). Similar num-
bers of TRAP-positive osteoclasts were observed in TRAF6
knockout mice and normal mice, but osteoclasts in TRAF6-
deficient mice did not form ruffled borders, structures nec-
essary for bone resorption (49). IL-1a receptors have been
shown to use TRAF6 as a signal-transducing molecule in
the target cells (51). We previously showed that IL-1a acti-
vated NF-kB in purified osteoclasts (39). IL-1a also in-
duced pit-forming activity of osteoclasts placed on dentine
slices (21). However, IL-1a failed to induce osteoclast dif-
ferentiation in M-BMMf cultures. These results suggest
that TRAF6 is a common signaling molecule responsible for
osteoclast activation induced by ODF/RANKL and IL-1a.
TRAF2 and/or its related TRAFs may be involved in the
differentiation of osteoclasts. Thus, ODF/RANKL–RANK
interaction induces signals necessary for both differentiation
and activation of osteoclasts (Fig. 9).
TNF-a stimulates osteoclastogenesis in the absence of
ODF/RANKL in vitro. However, this is not consistent with
the finding that the disruption of the ODF/RANKL gene
in mice showed a complete lack of osteoclasts in bone (40).
Recently, it was reported that TNF-a– and IL-1a–induced
bone resorption in mice was inhibited by concomitant
treatment with OCIF/OPG (52). Our preliminary experi-
ments showed that TNF-a as well as IL-1a upregulated ex-
pression of ODF/RANKL mRNA in osteoblasts/stromal
cells (data not shown), suggesting that a part of bone resorp-
tion induced by TNF-a and IL-1a could be inhibited by
OCIF/OPG. In fact, we reported that bone resorption in-
duced by parathyroid hormone and 1a,25(OH)2D3 was
completely inhibited by adding OCIF/OPG in an organ
culture system, but the inhibition by OCIF/OPG of IL-1a–
induced bone resorption was only partial (53). Ammann et
al. (54) also reported that transgenic mice insensitive to TNF
due to the overexpression of soluble TNF receptors are pro-
tected against bone loss due to estrogen deficiency. These re-
sults suggest that TNF-a and IL-1a are directly involved in
pathologically occurring bone resorption observed in in-
flammatory and metabolic bone diseases such as rheumatoid
arthritis, periodontitis, and/or postmenopausal osteoporosis
(24–27). Further studies will elucidate the biological signif-
icance of osteoclast differentiation and function stimulated by
a combination of TNF-a and IL-1a in pathological bone
resorption.
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